Safety of biologics in inflammatory bowel disease patients with COVID-19
ConclusionsOur findings advocate for the continued biologic therapy in IBD patients during the COVID-19 pandemic. Nevertheless, the incidence, severity, and outcomes related to COVID-19 in IBD patients ’ needs to be reassessed as data continues to emerge.
Source: International Journal of Colorectal Disease - Category: Gastroenterology Source Type: research
More News: Coronavirus | COVID-19 | Databases & Libraries | Gastroenterology | Inflammatory Bowel Disease | Intensive Care | Pandemics | Study